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Abstract
Background: Connective tissue growth factor (CTGF) has been shown to be implicated in tumor development
and progression. However, the role of CTGF in gastric cancer remains largely unknown.
Results: In this study, we showed that CTGF was highly expressed in gastric cancer tissues compared with
matched normal gastric tissues. The CTGF expression in tumor tissue was associated with histologic grade, lymph
node metastasis and peritoneal dissemination (P < 0.05). Patients with positive CTGF expression had significantly
lower cumulative postoperative 5 year survival rate than those with negative CTGF expression (22.9% versus 48.1%,
P < 0.001). We demonstrated that knockdown of CTGF expression significantly inhibited cell growth of gastric
cancer cells and decreased cyclin D1 expression. Moreover, knockdown of CTGF expression also markedly reduced
the migration and invasion of gastric cancer cells and decreased the expression of matrix metalloproteinase (MMP)-
2 and MMP-9. Animal studies revealed that nude mice injected with the CTGF knockdown stable cell lines featured
a smaller number of peritoneal seeding nodules than the control cell lines.
Conclusions: These data suggest that CTGF plays an important role in cell growth and invasion in human gastric
cancer and it appears to be a potential prognostic marker for patients with gastric cancer.
Keywords: Connective tissue growth factor, Stomach neoplasms, Cell proliferation, Invasiveness, Peritoneal
dissemination
Introduction
Despite significant advances in cancer research, cancer
remains a worldwide health problem and mortality due
to cancer remains high [1]. Gastric cancer is the second
leading cause of cancer-related death in the world while
there appears to be a decreasing trend in occurrence,
notably in Western countries; it is still commonly
reported in China and Japan [2,3]. Even though the
prognosis of patients with advanced gastric cancer
seems to have improved as a result of the standardiza-
tion of surgical techniques and recent advances in
chemotherapy, the 5-year postoperative survival rate
remains low [4,5]. Peritoneal metastasis is the most
common and significant cause of mortality after surgery
for gastric cancer [6,7]. However, the mechanisms of
peritoneal metastasis have not been clearly defined.
C o n n e c t i v et i s s u eg r o w t hf actor (CTGF), also known
as CCN2, is a member of the CCN family, including
cysteine-rich protein 61 (Cyr61), also known as CCN1,
and nephroblastoma-over expressed gene (Nov), also
known as CCN3, as well as Wisp-1/elm1 (CCN4),
Wisp-2/rcop1 (CCN5) and Wisp-3 (CCN6) [8,9]. CTGF
is believed to be a multifunctional signaling modulator
involved in a wide variety of biologic or pathologic pro-
cesses, such as angiogenesis, osteogenesis, fibrosis in
kidneys and skin, and tumor development [10-12].
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been well-studied [13], the function of CCN2 in cancer
is not as well-understood. Interestingly, CCN2 has been
identified as an oncogene in a variety of cancer types
but is considered a tumor-suppressor gene in other
forms of cancer [14]. Overexpression of CTGF is found
in prostate cancer [15], gliomas [16], breast cancer [17],
and adult acute lymphoblastic leukemia [18]. Increased
CTGF expression has been associated with progression
of cervical tumors [19], and esophageal squamous cell
carcinoma [20]. Conversely, in lung adenocarcinomas
[21] and colon cancers [22], overexpression of CTGF
inhibits invasion and metastasis of the cancer cells both
in vitro and in vivo.
Clinical studies have shown that overexpression of
CTGF was significantly correlated with lymph node
metastasis and poor prognosis in patients with gastric
cancer [23,24]. However, the precise role of CTGF in
gastric cancer is still unknown. In this study, we
detected CTGF expression in gastric cancer tissues. We
found that CTGF was overexpressed in gastric cancer,
and its expression was associated with aggressive beha-
vior of gastric cancer. We then used siRNA technology
to knockdown endogenous CTGF expression in gastric
cancer cells. We demonstrated that downregulation of
CTGF inhibited the growth and invasion of gastric can-
cer in vitro and attenuated peritoneal dissemination in
vivo. Our study strongly highlights the significance of
CTGF in the growth and invasion of gastric cancer, and
may provide a therapeutic target in gastric cancer.
Materials and methods
Reagents
Dimethyl sulfoxide (DMSO) and trypsin were purchased
from Sigma (St. Louis, MO, USA). DMEM, streptomycin
and other cell culture supplies were from GIBCOBRL
(Grand Island, NY, USA). Fetal bovine serum was from
Hyclone (Logan, UT, USA). MTT [3-(4, 5-dimethylthia-
zol-2-yl)-2, 5-diphenyltrazolium bromide] was obtained
from Fluka (Ronkonkoma, NY, USA). CTGF, cyclin D1,
matrix metalloproteinase (MMP)-2, MMP-3, MMP-9
and GAPDH primary antibody, as well as second anti-
body Rhodamine (TRITC)-conjugated affinipure goat
anti-mouse IgG were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). CTGF ELISA kit was
purchased from R&D (Minneapolis, MN, USA). Trizol
and Lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA, USA). SYBR
@Primescript™ RT-PCR kit
was from Takara Biotechnology, Japan.
Tissue specimens and immunohistochemical staining
Tumor specimens were obtained from 110 patients with
gastric cancer who underwent surgery at the Depart-
ment of Surgical Oncology, First Affiliated Hospital of
China Medical University during the period 2003-2005.
All patients underwent gastrctomy, and their clinical
and pathological data were available. Normal stomach
tissues were taken from the matched distal resected
margin of gastric cancer samples. All surgical specimens
were examined by experienced pathologists and the dis-
tal resected margin was tumor-free. The fresh tissues
were cut into small pieces, snap-frozen in liquid nitro-
gen immediately, and stored at -80°C until protein
extraction. The study protocol was reviewed and
approved by the Ethics Committee of China Medical
University.
For immunohistochemical staining, 4 μm histological
sections were deparaffinized with xylene and rehy-
drated through a graded series of alcohol. The sec-
tions were then boiled for 10 min in 0.01 M citrate
buffer and endogenous peroxidase was blocked by
incubation in 0.3% H2 O2 in methanol for 30 min.
Nonspecific binding was blocked by incubating slides
with normal goat serum for 30 min at room tempera-
ture. The sections were incubated overnight at 4°C
with 1:50 dilution of CTGF primary antibody. The
sections were exposed to biotin-labeled secondary
antibody for 1 h, to a streptavidin-peroxidase reaction
system, and then developed with DAB- H2 O2 .S t a i n -
ing was scored on the following scale: 0, no staining; 1
+, minimal staining; 2+, moderate to strong staining
in at least 20% of cells; 3+, strong staining in at least
50% of cells. Cases with 0 or 1+ staining were classi-
fied as negative, and cases with 2+ or 3+ staining were
classified as positive.
Cell Culture
Human gastric cancer cell lines, MKN-45, MKN-1, AGS,
SGC7901, BGC823 and MGC803 were obtained from
the Department of Cell Biology, China Medical Univer-
sity, China. They were cultured in DMEM containing
10% fetal bovine serum, 100 U/ml of penicillin, 100 ug/
ml of streptomycin at 37°C in a humidified atmosphere
of 5% CO2. The cells were dislodged using 0.25% trypsin
and 0.02 mol/L EDTA in PBS for subculture.
Construction of CTGF knockdown stable cell lines
Two small interfering RNA (siRNA) oligonucleotides
were synthesized to target two different regions in the
CTGF cDNA: GTGCATCCGTACTCCCAAA (PSC1)
and GCTAAATTCTGTGGAGTAT (PSC2). They were
cloned into the siRNA expression vector pGCsilen-
cer™U6.Neo.GFP. The nonspecific siRNA was used as
a negative control (PSNC). The siRNA expression plas-
mids were transfected into SGC7901 cells using Lipo-
fectamine 2000. The cells were screened with G418
(800 ug/ml), and the colonies were picked after 3
weeks, determined by RT-QPCR and Western blot.
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designated PSC1 cells, PSC2 cells or PSNC cells,
respectively.
Real-Time Quantitative Polymerase Chain Reaction (RT-
QPCR)
Total RNA was isolated from cell pellets using Trizol
reagent. Total RNA (1 ug) was converted to cDNA
using a RT (reverse transcriptase) reaction kit. Real-time
PCR was performed using Mx3000P real-time PCR sys-
tem according to the manufacturer’s instruction and
SYBR
® Premix ExTaq as a DNA specific fluorescent
dye. PCR was carried out for 40 cycles of 95°C for 5 s
and 60°C for 40 s. Primer sequences are shown in
table 1. The threshold cycle (Ct) was obtained and rela-
tive quantities were determined for each sample normal-
ized to GAPDH. Expressions of mRNA were calculated
using the ΔΔCt method [25].
Western blot analysis
Tissues or cells were lysed in RIPA buffer supplemented
with protease inhibitor mixture for 30 min at 4°C. The
cell lysates were then sonicated briefly and centrifuged
(14,000 g at 4°C) for 15 min to remove insoluble materi-
als. Equal amounts of protein were separated by SDS-
PAGE and transferred to a PVDF membrane. Mem-
branes were blocked with 5% nonfat dry milk and then
incubated with first antibody, followed by horseradish
peroxidase-conjugated secondary antibody. Protein
bands were visualized by ECL chemiluminescence
method.
Immunofluorescence and Confocal imaging
The cells on Lab-Tek tissue culture chamber slides were
fixed in cold 100% methanol for 10 min, and then
blocked with normal goat serum for 30 min. The cells
were incubated with the primary antibody overnight
at 4°C, washed 3 times in PBT (PBS with 1‰ Triton
X-100), and then incubated with second antibody conju-
gated with Rhodamine. The DNA dye DAPI was used to
stain the DNA. Cells were imaged on a Leica SP2AOBS
confocal microscope.
Conditioned medium (CM) collection and Enzyme-linked
immunoassay (ELISA)
3×1 0
5 cells were seeded in 100 mm tissue culture dish
with DMEM containing 10% fetal bovine serum for 2
days. Then the cells were washed twice with PBS and
incubated with 5 ml of serum free DMEM. 48 h later,
the conditioned medium was collected and centrifuged
at 2000 g for 5 min, passed through filters (pore size,
0.45 um) and stored at -80°C until use.
The levels of CTGF in the conditioned media from
gastric cancer cell lines were measured using human
Quantikine ELISA kit following the manufacturer’s
instructions.
MTT proliferation assay
The capability of cellular proliferation was assessed
using MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltrazolium bromide] assay. Approximately 5 × 10
3
cells were seeded into 96-well culture plates and cul-
tured in serum free DMEM for 24, 48, 72, and 96 h,
respectively. Then cells were incubated with 20 μl
MTT (10 mg/ml) for 4 h at 37°Cand 200 μlD M S O
was pipetted to solubilize the formazan product for 20
min at room temperature. The optical density (OD)
was determined using a spectrophotometer (Bio-Rad)
at a wavelength of 570 nm.
Colony formation assay
5×1 0
2 cells suspended in 2 ml of 0.3% agarose DMEM
medium containing 10% fetal bovine serum were plated
in 6-well plates on the top of existing 0.6% bottom agar-
ose with the same medium. The plates were incubated
at 37°C in a 5% CO2 incubator. After three weeks, cell
colonies > 0.1 mm in diameter were counted under a
microscopic field.
Cell invasion assay
The invasion was determined by an invasion chamber
assay. Cells (2 × 10
4) were seeded onto the top chamber
of a 24-well matrigel-coated micropore membrane filter
with 8 μm pores and the bottom chamber was filled
with 0.5 ml of DMEM with 10% fetal bovine serum as a
chemoattractant. After incubating for 24 h, non-invad-
ing cells (upper chamber) were gently removed by using
a cotton-tipped swab and invading cells (lower chamber)
were fixed using methanol and stained with trypan blue.
The invasive ability was determined by the number of
penetrating cells under a microscope at 200× magnifica-
tion for 10 random fields in each well.
Table 1 PCR Primer Sequences
Gene Primer Sequences (5’-3’) Forward and
Reverse
Product
(bp)
CTGF CTTGCGAAGCTGACCTGGAA
AAAGCTCAAACTTGATAGGCTTGGA
90
MMP-2 ATGACATCAAGGGCATTCAGGAG
TCTGAGCGATGCCATCAAATACA
135
MMP-3 GGGTGAGGACACCAGCATGA
CAGAGTGTCGGAGTCCAGCTTC
178
MMP-9 TCCCAGACCTGGGCAGATTC
GCAAAGGCGTCGTCAATCAC
124
Cyclin
D1
GATGCCAACCTCCTCAACGAC
CTCCTCGCACTTCTGTTCCTC
171
GAPDH GCACCGTCAAGGCTGAGAAC
TGGTGAAGACGCCAGTGGA
138
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The method of in vitro migration assay was using a
non-matrigel-coated 24-well Boyden chamber (8 μm,
Millipore). Cells (2 × 10
4)w e r es e e d e do n t ot h ei n s e r t s
suspended in 0.2 ml of serum-free DMEM medium.
Non-migrating cells were removed from the upper cham-
ber of the filter after incubation for 24 h. Migrated cells
were stained and quantified based on the procedure as
described earlier. Triplicate assays were performed for
each group of cells in invasion and migration assays, and
the results are expressed as means ± SD.
Gelatin zymography
MMP-2 and MMP-9 activity was determined by gelatin
zymography as described previously [26]. In brief, after
centrifugation the supernatant was separated and pro-
tein concentration determined; equal amounts of pro-
tein, added by sample buffer (Tris-HCl 1 M, pH 6.8,
Sodium dodecyl sulphate (SDS) 2%, glycerol 10%) were
applied to 7.5% SDS-polyacrylamide gel containing 1
mg/ml gelatine. After electrophoresis, SDS was removed
from the gel by washing twice with 2.5% TritonX-100
f o r1h .A f t e rab r i e fr i n s e ,t h eg e lw a si n c u b a t e da t3 7 °
C for 18 h in buffer, pH 7.6, containing 100 mM Tris-
HCl, 10 mM CaCl2 , 20 mM NaCl. The gel was stained
with1% Coomassie Brilliant Blue R250 for 2 h and then
treated with destaining solution (40% methanol, 10%
acetic acid, 50% distilled water). Proteolytic activity was
detected as clear bands against the background stain of
undigested substrate in the gel.
Animal study of peritoneal implantation
This experiment was conducted in accordance with the
guideline issued by the State Food and Drug Adminis-
tration (SFDA of China). The animals were housed and
cared for in accordance with the guidelines established
by the National Science Council of Republic China.
Female BALB/c nude mice, 35-40 days old and weigh-
ing 20-22 g, were supplied by Shanghai Slac Laboratory
Animal Limited Company. The mice were kept under
sterile conditions and fed a sterilized mouse diet and
water. Animals were anaesthetized via inhalation of iso-
flurance. PSC1, PSC2, PSNC and SGC7901 cells (1 ×
10
7 cells) were suspended in 0.5 ml DMEM and inocu-
lated into the abdominal cavity of test mice. The mice
were sacrificed six weeks later, and any disseminated
nodules present on the mesentery and diaphragm were
evaluated.
Statistical analysis
All values in the text and figures are presented as mean
± SD. Overall survival rates were determined using
Kaplan-Meier estimator, an event being defined as death
for cancer correlated cause. The log-rank test was used
to identify differences between the survival curves of dif-
ferent patients’ groups. In univariate analysis, 2-tailed c
2
tests for categorical variables and 2-tailed t test for con-
tinuous variables were used for statistical comparisons.
Values of p < 0.05 were taken to show a significant dif-
ference between means.
Results
CTGF is overexpressed in gastric cancers and correlated
with clinicopathological features of gastric cancer
patients
We determined the CTGF expression in gastric cancer
tissues and matched distal normal tissues. Figure 1A
illustrated CTGF expression in five randomly picked
patients. Elevated levels of CTGF protein were found in
human gastric cancer tissues compared with the paired
normal tissues from the patients. This was also con-
firmed by immunohistochemical staining (Figure 1B).
Moreover, in order to further investigate the correlation
between expression of CTGF and clinicopathological
features, 110 samples were used for examination with
immunohistochemical staining. Statistical analysis
revealed positive CTGF expression was significantly
associated with histologic grade, lymph node metastasis
and peritoneal dissemination compared with those
patients with negative CTGF expression (Table 2). Posi-
tive CTGF expression was more frequently detected in
cases of lymph nodes metastasis (P = 0.012). Levels of
CTGF expression were increased significantly in undif-
ferentiated gastric cancers compared with differentiated
gastric cancers (P = 0.039). And the expression of
CTGF protein was significantly correlated with the
development of peritoneal dissemination of gastric can-
cer (P = 0.011). Calculation of the survival duration of
the 110 involved patients by the Kaplan-Meier method
revealed that the patients who featured CTGF-positive
tumors demonstrated a shorter survival when compared
with those patients who suffered from CTGF-negative
tumors (Figure 1C, P < 0.001).
Expression of CTGF in human gastric cancer cell lines and
siRNA-mediated silence
First, we examined CTGF expression in six gastric can-
cer cell lines (MKN-45, MKN-1, AGS, SGC7901,
B G C 8 2 3a n dM G C 8 0 3 )b yW e s t e r nb l o t .C T G Fw a s
detected in all cell lines evaluated, and with SGC7901
cells expressing the highest level (Figure 2A). Therefore,
SGC7901 cells were selected as the model for the subse-
quent function studies. Because biologically active
CTGF is both secreted and expressed in the cytoplasm
[8,27], we also measured the level of secreted CTGF in
the conditioned media of these gastric cancer cell lines
by ELISA, which was coincided with the level of CTGF
in the cytoplasm of each cell line (Figure 2B).
Jiang et al. Molecular Cancer 2011, 10:122
http://www.molecular-cancer.com/content/10/1/122
Page 4 of 12To study the function of CTGF in SGC7901 cells, the
CTGF knockdown stable cell lines were used to analyze
the silencing effect. As shown in Figure 2B, the level of
secreted CTGF in the conditioned medium was signifi-
cantly decreased in the siRNA-stable transfected cells
compared to control. Western blot and immunofluores-
cence staining showed that expression of CTGF protein
in the cytoplasm decreased markedly in the CTGF
knockdown stable cell lines (Figure 2C, D). Furthermore,
the expression of CTGF mRNA was also significantly
decreased in the CTGF knockdown stable cell lines
(Figure 2E).
Knockdown of CTGF expression inhibits the growth
of gastric cancer cells
The colony formation assay was used to evaluate the
growth of the cells in which CTGF was silenced. As
shown in Figure 3A, CTGF knockdown stable cells
(PSC1 and PSC2) formed significantly fewer colonies on
soft agar compared to SGC7901 and PSNC cells (83 ±
10, 90 ± 15 versus 30 ± 7 and 20 ± 5, respectively). To
further test the negative effect of CTGF knockdown on
gastric cancer cell growth, MTT assay was performed
and growth curves were generated (Figure 3B). As
shown by the curves, both PSC1 and PSC2 cells prolifer-
ated slower than PSNC cells and SGC7901 cells during
the first 96 h after the cells were plated. The dramatic
reduction of colony formation and growth of CTGF
silenced cells suggested CTGF suppression might nega-
tively regulate gastric cancer cell growth. RT-QPCR
showed that mRNA levels of cell cycle related protein
cyclin D1 were down regulated in the two CTGF knock-
down stable cell lines compared with PSNC and
SGC7901 (Figure 3C). Consistent with this result, we
observed a marked reduction of cyclin D1 protein
expression in CTGF knockdown cells PSC1 and PSC2
(Figure 3D). Interestingly, treatment with conditioned
medium of SGC7901 which secreted a large amount of
CTGF was able to rescue the cyclin D1 downregulation
and restore the cell proliferation in CTGF knockdown
stable cells. These data indicated that CTGF suppression
might negatively regulate gastric cancer cell growth and
decrease cyclin D1 expression.
Knockdown of CTGF expression inhibits the migration
and invasion of gastric cancer cells
Cell migration and invasion are critical processes in
tumor metastasis. We investigated cell migration by
non-matrigel-coated Boyden chamber and cell invasion
by matrigel-coated invasion chamber assays, respectively.
In the migration assays (Figure 4A), migration rates of
the PSC1 and PSC2 cells were significantly decreased
when compared to control (P < 0.05). As shown in
Figure 4B, CTGF knockdown also markedly reduced cell
invasion properties when compared to control. Cell
invasion rates of PSC1 and PSC2 cells were decreased
by 61.4% and 55.8%, respectively. RT-QPCR and
Western blot showed that MMP-2 and MMP-9 were
down regulated in the two stable clones compared with
control cells (Figure 4C; D). In contrast, MMP-3 didn’t
Figure 1 Overexpression of CTGF in gastric cancer with worse prognosis. A. Western blot analysis demonstrated the CTGF expression in
gastric cancer tissues and matched distal normal tissues from five randomly selected gastric cancer patients. B. Immunohistochemistry results of
CTGF expression in paired gastric cancer tissue samples. C. Kaplen-Meir survival curves for 110 patients with gastric cancer, grouped according to
CTGF expression.
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Furthermore, zymography analysis showed the activities
of both MMP-2 and MMP-9 in the siRNA-stable trans-
fected cells were significantly lower than those in the
control cells (Figure 4E). Interestingly, treatment with
conditioned medium of SGC7901 which secreted a large
amount of CTGF induced the re-expression of MMP-2
and MMP-9 and restored the migration and invasion of
the CTGF knockdown stable cells. These results sug-
gested that knockdown of CTGF expression reduced the
migration and invasion of gastric cancer cells and
decreased the expression of MMP-2 and MMP-9.
Downregulation of CTGF inhibits peritoneal dissemination
of gastric cancer in vivo
To explore the effects of CTGF on the peritoneal disse-
mination of gastric cancer cells in vivo, we inoculated
different cells into nude mice. SGC7901 cells, control
stable cell line (PSNC), and CTGF knockdown stable
cells (PSC1 and PSC2) were injected into four separate
groups of nude mice. As consequence of such treatment,
the measurable suppression of peritoneal dissemination
in mice injected with CTGF knockdown stable cells as
compared with those injected with SGC7901 cells or
PSNC cells was noted (Figure 5A). Quantitatively, 117 ±
20 disseminated nodules were noted for test mice inocu-
lated with SGC7901 cells and 137 ± 26 disseminated
nodules were noted for mice inoculated with PSNC
cells. In contrast, significant fewer disseminated nodules
were able to be observed for mice injected with CTGF
knockdown stable cells (Figure 5B).
Discussion
The most extensive literature to date regarding CTGF
defines its role in wound-healing and fibrotic disease.
Recently, several studies implicate CTGF in tumor
development and tumor cell survival [28-30]. Nonethe-
less, the exact role of CTGF in tumor progression is not
definite, and the function of CTGF in tumor cell biology
of gastric cancer has not been thoroughly investigated.
To address these issues, we evaluated CTGF expression
with regard to possible direct correlations with cell
growth and invasion of gastric cancer cells. Moreover,
we further investigated the effects of CTGF on perito-
neal dissemination of gastric cancer cells in vivo.
In this study, our results showed that CTGF was
highly expressed in gastric cancer tissues compared with
matched normal gastric tissues. The expression of
CTGF in undifferentiated gastric cancer was significantly
higher than those in differentiated gastric cancer. The
CTGF expression in tumor tissue was associated with
lymph node metastasis and peritoneal dissemination.
Furthermore, patients with positive CTGF expression
had significantly lower cumulative postoperative 5 year
survival rate (22.9%) than those with negative CTGF
expression (48.1%, Figure 1C). These results suggested
that CTGF might be involved in progression and metas-
tasis of gastric cancer. Moreover, CTGF might be a use-
ful prognostic marker.
Several recent studies have revealed that CTGF regu-
late cell growth in esophageal cancer cells and pancrea-
tic cancer cells [20,30]. However, little is known about
the effect of CTGF expression on cell growth of gastric
cancer cells. Our results showed that CTGF suppression
resulted in inhibition of cell proliferation and clonogenic
growth. Changes in cell growth might be key factors in
regulating cancer progression [31]. Therefore, our
Table 2 Association between CTGF expression and
clinicopathologic characteristics of patients with gastric
cancer (n = 110)
CTGF expression
Negative Positive P value
Gender
Male 33 34 0.779
Female 20 23
Age (years)
≤ 65 35 40 0.642
>6 5 1 8 1 7
Tumor size (cm)
< 5 26 25 0.585
≥ 52 7 3 2
Tumor location
Lower 42 37 0.413
Middle 5 8
Upper 3 6
Entire 3 6
Histologic grade
Differentiated 26 17 0.039*
Undifferentiated 27 40
Lauren grade
Intestinal 28 21 0.108
Diffuse 25 36
Lymph node metastasis
Negative 23 12 0.012*
Positive 30 45
TNM stage
I 11 8 0.080
II 15 9
III 20 22
IV 7 18
Hepatic metastasis
Negative 50 55 0.588
Positive 3 2
Peritoneal dissemination
Negative 50 44 0.011*
Positive 3 13
*P < 0.05; CTGF, connective tissue growth factor.
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Page 6 of 12Figure 2 Expression of CTGF in gastric cancer cell lines and knockdown of CTGF by siRNA. A. Western blot showing the expression of
CTGF in 6 gastric cancer cell lines. GAPDH served as protein loading control. B. CTGF in conditioned media of 6 gastric cancer cell lines and
stable transfected cells was analyzed by ELISA. Results are expressed as pg/ml/1 × 10
6cells (mean ± SD, n = 4). C. Western blot analysis of CTGF
protein expression in SGC7901, PSNC and CTGF knockdown stable cell lines (PSC1 and PSC2). D. Immunofluorescence analysis of CTGF
expression. E. RT-QPCR showing CTGF mRNA levels in SGC7901, PSNC and CTGF knockdown stable cell lines (PSC1 and PSC2). Data are
expressed as a fold change relative to control (control is SGC7901). Values are given as mean ± SD of three experiments. *P < 0.05 as compared
to control.
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cer development. We also found that expression of
cyclin D1 decreased with suppression of CTGF. It is
well known that cyclin D1 is important in the develop-
ment and progression of numerous cancers [32,33].
Cyclin D1 plays a crucial role in the progression of cell
cycle and determines mitochondrial function and size
[34-36]. Cyclin D1 regulates cell cycle progression,
explaining in part how CTGF influences the growth of
gastric cancer cells.
Cancer metastasis is a major cause of morbidity in
cancer patients. Cancer metastasis consists of multiple
sequential steps; invasion is one of the most characteris-
tic steps during the cascade of metastasis. Many studies
have demonstrated the importance of invasion in the early
stages of metastasis [37,38]. In this study, stable transfec-
tion with CTGF siRNA into human gastric cancer cells
could obviously inhibit cell invasion and migration ability
of SGC7901 (Figure 4A; B), which suggested that CTGF
m i g h tb ei n v o l v e di nm e t a s t a s i so fg a s t r i cc a n c e r .T h e
initial step of tumor cell invasion is characterized by the
breakdown of the base membrane, a process known to be
dependent on type IV collagen-degrading enzymes, mainly
MMP-2 and MMP-9 [39]. The activation of MMP-2 and
MMP-9 is in a tumor-specific manner and correlates with
metastatic abilities and poor prognosis [40,41]. The data
showed that the expression levels of MMP-2 and MMP-9
significantly decreased in the CTGF knockdown stable cell
Figure 3 Knockdown of CTGF expression inhibits the growth of gastric cancer cells. A. Colony formation assay. B. MTT proliferation assay.
C. Knockdown of CTGF down regulated the mRNA level of cyclin D1. D. Knockdown of CTGF down regulated the protein level of cyclin D1.
PSC1/PSC2+CM of SGC7901: PSC1 or PSC2 cells were incubated with conditioned medium (CM) of SGC7901. All results were reproducible in
three independent experiments. *P < 0.05 as compared to control (control is SGC7901).
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Page 8 of 12Figure 4 Knockdown of CTGF expression inhibits the migration and invasion of gastric cancer cells. A. Cell migration assay. B.C e l l
invasion assay. Migration and invasion cells were fixed and stained, and representative fields were photographed. For quantification, the cells
were counted in 10 random fields under a light microscope (×200). Triplicate assays were performed for each group of cells in invasion and
migration assays, and the results are expressed as means ± SD. C. RT-QPCR was done for analysis the mRNA expression of MMP-2, MMP-3, and
MMP-9 in the CTGF knockdown stable cell lines and control cells. Bars represent the mean ± SD of three experiments. D. The protein levels of
MMP-2, MMP-3, and MMP-9 were detected by Western blot. GAPDH served as protein loading control. E. Gelatin zymography analysis for the
activities of MMP-2 and MMP-9. PSC1/PSC2+CM of SGC7901: PSC1 or PSC2 cells were incubated with conditioned medium (CM) of SGC7901.*P
< 0.05 as compared to control (control is SGC7901).
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tion of MMP-2 and MMP-9 contributed to the reduced
invasion of the CTGF knockdown stable gastric cancer
cells.
Peritoneal dissemination is not only the most frequent
pattern of gastric cancer recurrence, but it is also a
major cause of death among advanced gastric cancer
patients [42]. Although the presence of peritoneal
metastasis reveals a strong impact for patient prognosis,
the molecular mechanisms by which gastric cancer cells
actually acquire the ability to undergo peritoneal disse-
mination remains to be clarified. In the present study,
the CTGF expression in tumor tissue was associated
with peritoneal dissemination. And the downregulation
of CTGF was resulted in the inhibition of cell growth,
migration and invasion of gastric cancer cells. Since cell
growth and invasion are the critical steps of peritoneal
dissemination, we investigated the effects of CTGF on
the peritoneal dissemination of gastric cancer cells in
vivo. We found CTGF knockdown stable cell lines
(PSC1 and PSC2) had significantly diminished peritoneal
metastatic ability compared with control cells. These
results indicated CTGF might play an important role in
the peritoneal dissemination of gastric cancer.
Conclusions
In summary, overexpression of CTGF was associated
with progression, metastasis and prognosis of gastric
cancer. With siRNA technology, we showed that down-
regulation of CTGF expression could inhibit the cell
Figure 5 Knockdown of CTGF inhibits gastric cancer SGC7901 xenograft peritoneal dissemination. SGC7901, PSNC and CTGF knockdown
stable cell lines (PSC1 and PSC2) were injected intraperitoneally as described under “Material and Methods”. 6 weeks later, the mice were
sacrificed, photographed, dissected and any disseminated nodules present on the mesentery and diaphragm were counted. A. The photograph
of nude mice with peritoneal dissemination from each group. B. The disseminated nodules were evaluated. Each bar represents the mean ± SD
(n = 5 for each group). *P < 0.05 as compared to control (control is SGC7901).
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Page 10 of 12growth and invasion of gastric cancer cells in vitro.
Furthermore, downregulation of CTGF expression could
attenuate peritoneal dissemination of gastric cancer cells
in vivo. These data provide a sound scientific rationale
for further investigation into targeting CTGF in gastric
cancer.
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